Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.3389/fimmu.2018.00608

http://scihub22266oqcxt.onion/10.3389/fimmu.2018.00608
suck pdf from google scholar
29632539!5879147!29632539
unlimited free pdf from europmc29632539    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid29632539      Front+Immunol 2018 ; 9 (?): 608
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages #MMPMID29632539
  • Bayik D; Tross D; Klinman DM
  • Front Immunol 2018[]; 9 (?): 608 PMID29632539show ga
  • Monocytic myeloid-derived suppressor cells (mMDSC) accumulate within tumors where they create an immunosuppressive milieu that inhibits the activity of cytotoxic T and NK cells thereby allowing cancers to evade immune elimination. The toll-like receptors 7/8 agonist R848 induces human mMDSC to mature into inflammatory macrophage (MAC(inflam)). This work demonstrates that TNFalpha, IL-6, and IL-10 produced by maturing mMDSC are critical to the generation of MAC(inflam). Neutralizing any one of these cytokines significantly inhibits R848-dependent mMDSC differentiation. mMDSC cultured in pro-inflammatory cytokine IFNgamma or the combination of TNFalpha plus IL-6 differentiate into MAC(inflam) more efficiently than those treated with R848. These mMDSC-derived macrophages exert anti-tumor activity by killing cancer cells. RNA-Seq analysis of the genes expressed when mMDSC differentiate into MAC(inflam) indicates that TNFalpha and the transcription factors NF-kappaB and STAT4 are major hubs regulating this process. These findings support the clinical evaluation of R848, IFNgamma, and/or TNFalpha plus IL-6 for intratumoral therapy of established cancers.
  • |Cell Differentiation[MESH]
  • |Cells, Cultured[MESH]
  • |Cytokines/metabolism[MESH]
  • |Cytotoxicity, Immunologic[MESH]
  • |Gene Expression Profiling[MESH]
  • |Humans[MESH]
  • |Imidazoles/pharmacology[MESH]
  • |Immune Tolerance[MESH]
  • |Immunotherapy/*trends[MESH]
  • |Inflammation Mediators/metabolism[MESH]
  • |Inflammation/*immunology[MESH]
  • |Monocytes/*physiology[MESH]
  • |Myeloid-Derived Suppressor Cells/*physiology[MESH]
  • |NF-kappa B/genetics[MESH]
  • |Neoplasms/*immunology[MESH]
  • |STAT4 Transcription Factor/genetics[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box